INTERPACE BIOSCIENCES, INC.

INTEGRAGENALINT · BiotechFrance

72% matchPublic

IntegraGen develops genomic tests, molecular diagnostic products, and bioinformatics software for researchers, clinicians, and biopharma companies. The company specializes in oncology and genetic diseases, offering next-generation sequencing services, data analysis tools, and biomarker identification to support clinical research and diagnostics.

VeracyteVCYT · BiotechSouth San Francisco, United States

69% matchPublicAI 37/100 ▼Green 0/100 ▼

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Pathwork Diagnostics developed molecular diagnostic tests for cancer, notably the Tissue of Origin test, which analyzes tumor gene-expression patterns to help identify the likely primary site of metastatic cancers when the origin is unknown. Its products served pathologists and oncologists managing patients with cancers of unknown primary.

CANCER GENETICS, INCBiotechnologyUnited States

68% matchPrivate

Cancer Genetics, Inc. is a biotechnology company headquartered in Rutherford, New Jersey, with operational history including facilities in Los Angeles, California. The company provides specialized oncology-focused diagnostic products, genomic services, and biomarker testing.

OncoCyte Corp0KCC · BiotechUnited States

67% matchPublic

Insight Molecular Diagnostics Inc., which transitioned from its former name OncoCyte Corporation in June 2025, functions as a specialized diagnostics enterprise with operations extending across the United States and internationally. The company's core activities involve pioneering and marketing a diverse array of diagnostic solutions, including laboratory developed tests, kitted products intended solely for research, and comprehensive kitted clinical tests. Its developmental pipeline features advanced tools such as DetermaCNI, a blood-based monitoring system engineered to identify early cancer progression promptly after just one treatment cycle. Another significant offering, DetermaIO, is a gene expression assay designed to evaluate the tumor microenvironment, thereby helping to predict a patient's potential response to immunotherapies. In the critical field of organ transplantation, Insight Molecular Diagnostics provides several vital monitoring products. Both VitaGraft Kidney and VitaGraft Liver are blood-based tests that precisely measure the concentration of donor-derived cell-free DNA (dd-cfDNA) to assess the status of kidney and liver transplants, respectively. Additionally, GraftAssure represents a sophisticated dd-cfDNA test that leverages droplet digital PCR (ddPCR) technology to quantify dd-cfDNA levels by examining 48 predefined single nucleotide polymorphisms (SNPs). Beyond its product offerings, the company delivers various specialized services, including biomarker discovery, comprehensive assay design and development, support for clinical trials, and a range of general biomarker testing. Furthermore, Insight Molecular Diagnostics maintains a strategic partnership with Bio-Rad Laboratories, Inc. This collaboration focuses on the advancement and commercialization of kitted transplant products for both research use only and in vitro diagnostics applications, utilizing Bio-Rad's proprietary ddPCR instruments and reagents. Founded in 2009, the company's headquarters are situated in Nashville, Tennessee.

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.